Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Study Information
Alliance Study ID: NCCTG-N0021
NCT Study ID (ClinicalTrials.gov): NCT00017186
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Scott Okuno, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information